Cargando…

Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules

BACKGROUND: Myotonic dystrophy type 1 (DM1) is the most common muscle dystrophy in adults. The disease is caused by a triplet expansion in the 3'end of the myotonic dystrophy protein kinase (DMPK) gene. In order to develop a human cell model for investigation of possible effects of antisense an...

Descripción completa

Detalles Bibliográficos
Autores principales: Larsen, Jan, Pettersson, Olof J, Jakobsen, Maria, Thomsen, Rune, Pedersen, Christina B, Hertz, Jens M, Gregersen, Niels, Corydon, Thomas J, Jensen, Thomas G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226528/
https://www.ncbi.nlm.nih.gov/pubmed/22078098
http://dx.doi.org/10.1186/1756-0500-4-490
_version_ 1782217633668530176
author Larsen, Jan
Pettersson, Olof J
Jakobsen, Maria
Thomsen, Rune
Pedersen, Christina B
Hertz, Jens M
Gregersen, Niels
Corydon, Thomas J
Jensen, Thomas G
author_facet Larsen, Jan
Pettersson, Olof J
Jakobsen, Maria
Thomsen, Rune
Pedersen, Christina B
Hertz, Jens M
Gregersen, Niels
Corydon, Thomas J
Jensen, Thomas G
author_sort Larsen, Jan
collection PubMed
description BACKGROUND: Myotonic dystrophy type 1 (DM1) is the most common muscle dystrophy in adults. The disease is caused by a triplet expansion in the 3'end of the myotonic dystrophy protein kinase (DMPK) gene. In order to develop a human cell model for investigation of possible effects of antisense and RNAi effector molecules we have used lentiviral mediated myoD-forced myogenesis of DM1 patient fibroblasts. FINDINGS: Transduced fibroblasts show a multinuclear phenotype and express the differentiation marker myogenin. Furthermore, fluorescence in situ hybridization (FISH) analysis revealed a statistical significant increase in the amount of nuclear foci in DM1 patient fibroblasts after myogenesis. Finally, no nuclear foci were found after treatment with oligonucleotides targeting the repeat expansions. CONCLUSIONS: The abundance of nuclear foci in DM1 patient fibroblasts increase following myogenesis, as visualized by FISH analysis. Foci were eradicated after treatment with antisense oligonucleotides. Thus, we propose that the current cell model is suitable for testing of novel treatment modalities.
format Online
Article
Text
id pubmed-3226528
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32265282011-11-30 Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules Larsen, Jan Pettersson, Olof J Jakobsen, Maria Thomsen, Rune Pedersen, Christina B Hertz, Jens M Gregersen, Niels Corydon, Thomas J Jensen, Thomas G BMC Res Notes Short Report BACKGROUND: Myotonic dystrophy type 1 (DM1) is the most common muscle dystrophy in adults. The disease is caused by a triplet expansion in the 3'end of the myotonic dystrophy protein kinase (DMPK) gene. In order to develop a human cell model for investigation of possible effects of antisense and RNAi effector molecules we have used lentiviral mediated myoD-forced myogenesis of DM1 patient fibroblasts. FINDINGS: Transduced fibroblasts show a multinuclear phenotype and express the differentiation marker myogenin. Furthermore, fluorescence in situ hybridization (FISH) analysis revealed a statistical significant increase in the amount of nuclear foci in DM1 patient fibroblasts after myogenesis. Finally, no nuclear foci were found after treatment with oligonucleotides targeting the repeat expansions. CONCLUSIONS: The abundance of nuclear foci in DM1 patient fibroblasts increase following myogenesis, as visualized by FISH analysis. Foci were eradicated after treatment with antisense oligonucleotides. Thus, we propose that the current cell model is suitable for testing of novel treatment modalities. BioMed Central 2011-11-11 /pmc/articles/PMC3226528/ /pubmed/22078098 http://dx.doi.org/10.1186/1756-0500-4-490 Text en Copyright ©2011 Jensen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Larsen, Jan
Pettersson, Olof J
Jakobsen, Maria
Thomsen, Rune
Pedersen, Christina B
Hertz, Jens M
Gregersen, Niels
Corydon, Thomas J
Jensen, Thomas G
Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules
title Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules
title_full Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules
title_fullStr Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules
title_full_unstemmed Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules
title_short Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules
title_sort myoblasts generated by lentiviral mediated myod transduction of myotonic dystrophy type 1 (dm1) fibroblasts can be used for assays of therapeutic molecules
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226528/
https://www.ncbi.nlm.nih.gov/pubmed/22078098
http://dx.doi.org/10.1186/1756-0500-4-490
work_keys_str_mv AT larsenjan myoblastsgeneratedbylentiviralmediatedmyodtransductionofmyotonicdystrophytype1dm1fibroblastscanbeusedforassaysoftherapeuticmolecules
AT petterssonolofj myoblastsgeneratedbylentiviralmediatedmyodtransductionofmyotonicdystrophytype1dm1fibroblastscanbeusedforassaysoftherapeuticmolecules
AT jakobsenmaria myoblastsgeneratedbylentiviralmediatedmyodtransductionofmyotonicdystrophytype1dm1fibroblastscanbeusedforassaysoftherapeuticmolecules
AT thomsenrune myoblastsgeneratedbylentiviralmediatedmyodtransductionofmyotonicdystrophytype1dm1fibroblastscanbeusedforassaysoftherapeuticmolecules
AT pedersenchristinab myoblastsgeneratedbylentiviralmediatedmyodtransductionofmyotonicdystrophytype1dm1fibroblastscanbeusedforassaysoftherapeuticmolecules
AT hertzjensm myoblastsgeneratedbylentiviralmediatedmyodtransductionofmyotonicdystrophytype1dm1fibroblastscanbeusedforassaysoftherapeuticmolecules
AT gregersenniels myoblastsgeneratedbylentiviralmediatedmyodtransductionofmyotonicdystrophytype1dm1fibroblastscanbeusedforassaysoftherapeuticmolecules
AT corydonthomasj myoblastsgeneratedbylentiviralmediatedmyodtransductionofmyotonicdystrophytype1dm1fibroblastscanbeusedforassaysoftherapeuticmolecules
AT jensenthomasg myoblastsgeneratedbylentiviralmediatedmyodtransductionofmyotonicdystrophytype1dm1fibroblastscanbeusedforassaysoftherapeuticmolecules